Fairhaven Wealth Management LLC Sells 461 Shares of Johnson & Johnson (NYSE:JNJ)

Fairhaven Wealth Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,099 shares of the company’s stock after selling 461 shares during the period. Fairhaven Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,027,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in JNJ. Stack Financial Management Inc lifted its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Stack Financial Management Inc now owns 113,279 shares of the company’s stock worth $16,382,000 after buying an additional 516 shares during the last quarter. Pine Valley Investments Ltd Liability Co increased its position in Johnson & Johnson by 18.7% during the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 117,542 shares of the company’s stock worth $16,999,000 after acquiring an additional 18,554 shares during the period. BankPlus Trust Department bought a new stake in Johnson & Johnson in the 4th quarter valued at $392,000. IFP Advisors Inc grew its position in Johnson & Johnson by 6.2% in the 4th quarter. IFP Advisors Inc now owns 32,252 shares of the company’s stock worth $4,665,000 after purchasing an additional 1,873 shares during the last quarter. Finally, RWC Asset Management LLP increased its holdings in shares of Johnson & Johnson by 38.1% during the 4th quarter. RWC Asset Management LLP now owns 326,297 shares of the company’s stock worth $47,189,000 after purchasing an additional 89,969 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.4 %

Shares of JNJ opened at $163.69 on Friday. The stock has a fifty day moving average price of $150.48 and a two-hundred day moving average price of $156.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $394.11 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.